Hexocyclium

DB06787

small molecule approved

Deskripsi

Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable side effect profiles.

Struktur Molekul 2D

Berat 317.496
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

516 Data
Aclidinium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Hexocyclium.
Mirabegron The risk or severity of urinary retention can be increased when Hexocyclium is combined with Mirabegron.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Hexocyclium.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Hexocyclium.
Tiotropium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Hexocyclium is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum toxin type A.
Glucagon Hexocyclium may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Hexocyclium may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Hexocyclium is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Hexocyclium is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Hexocyclium is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Hexocyclium is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Hexocyclium is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Hexocyclium is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Hexocyclium is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Hexocyclium is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Hexocyclium is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Hexocyclium is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Hexocyclium is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Hexocyclium is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Hexocyclium is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Hexocyclium is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Hexocyclium is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Hexocyclium is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Hexocyclium is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Hexocyclium is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Hexocyclium.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hexocyclium.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Hexocyclium.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Hexocyclium.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Hexocyclium.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Hexocyclium.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Hexocyclium.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hexocyclium.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Hexocyclium.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Hexocyclium.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hexocyclium.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Hexocyclium.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Hexocyclium.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Hexocyclium.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Hexocyclium.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Hexocyclium.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Hexocyclium.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hexocyclium.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hexocyclium.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Hexocyclium.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Hexocyclium.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Hexocyclium.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexocyclium.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Hexocyclium.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Hexocyclium.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Hexocyclium.
Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Hexocyclium.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Hexocyclium.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Hexocyclium.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hexocyclium.
Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Hexocyclium.
Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexocyclium.
Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Hexocyclium.
Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hexocyclium.

Target Protein

Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M4 CHRM4

Referensi & Sumber

Synthesis reference: U.S. Patent 2,907,765.
Artikel (PubMed)
  • PMID: 8075869
    Waelbroeck M, Camus J, Tastenoy M, Feifel R, Mutschler E, Tacke R, Strohmann C, Rafeiner K, Rodrigues de Miranda JF, Lambrecht G: Binding and functional properties of hexocyclium and sila-hexocyclium derivatives to muscarinic receptor subtypes. Br J Pharmacol. 1994 Jun;112(2):505-14.
  • PMID: 13487546
    KASICH AM, FEIN HD: Hexocyclium methosulfate in active duodenal ulcer; evaluation of a new anticholinergic drug in conventional and long-acting forms, especially its effect on gastric pH as studied in 48-hour analysis. Am J Dig Dis. 1958 Jan;3(1):12-23.
  • PMID: 21951
    Grundhofer B, Gibaldi M: Biopharmaceutic factors that influence effects of anticholinergic drugs: comparison of propantheline, hexocyclium, and isopropamide. J Pharm Sci. 1977 Oct;66(10):1433-5.
Textbook
  • ISBN: 978-0-7020-3471-8
    Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Tral — Abbott
  • Traline — Abbott

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul